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In Brief
Therapeutic approaches aimed at
expanding regulatory T cells in the gut to
promote immune tolerance in patients
with inflammatory bowel disease (IBD)
are of clinical significance. Goettel et al.
establish a humanized murine model of
IBD driven by human T cells and find that
activation of AHR by the non-toxic
agonist ITE can prevent experimental
colitis.
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Existing therapies for inflammatory bowel disease
that are based on broad suppression of inflammation
result in variable clinical benefit and unwanted side
effects. A potential therapeutic approach for promot-
ing immune tolerance is the in vivo induction of reg-
ulatory T cells (Tregs). Here we report that activation
of the aryl hydrocarbon receptor using the non-
toxic agonist 2-(10H-indole-30-carbonyl)-thiazole-4-
carboxylic acid methyl ester (ITE) induces human
Tregs in vitro that suppress effector T cells through
a mechanism mediated by CD39 and Granzyme B.
We then developed a humanized murine system
whereby human CD4+ T cells drive colitis upon expo-
sure to 2,4,6-trinitrobenzenesulfonic acid and as-
sessed ITE as a potential therapeutic. ITE adminis-
tration ameliorated colitis in humanized mice with
increased CD39, Granzyme B, and IL10-secreting
human Tregs. These results develop an experimental
model to investigate humanCD4+ T responses in vivo
and identify the non-toxic AHR agonist ITE as a
potential therapy for promoting immune tolerance
in the intestine.
INTRODUCTION
Inflammatory bowel diseases (IBDs) are complex inflammatory
disorders of the intestine that are generally associated with
defects in mucosal immune regulation (Khor et al., 2011). Damp-
ening the inflammatory response to re-establish immune toler-
ance is a major therapeutic strategy for IBD treatment. Current
clinical approaches often involve broad suppression of the im-
mune system, resulting in limited clinical benefit and concomi-
tant risk for opportunistic infections and other side effects
(Beaugerie, 2012; Calabrese, 2006). More recently, the use of1318 Cell Reports 17, 1318–1329, October 25, 2016 ª 2016 The Auth
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has proved effective with nearly half of treated patients demon-
strating a clinical response (Ben-Horin et al., 2014). However,
these beneficial effects are often self-limited and highlight
the need for new therapies that promote long-lasting immune
tolerance.
Since the initial description that the thymus has critical
immunological function (Burnet and Holmes, 1962; Miller,
1961) and subsequent work by many that the thymus has func-
tions independent of elimination of autoreactive T cells (Le
Douarin et al., 1996), there has been a concerted effort to
understand the mechanisms of immunological tolerance.
Extensive experimentation has defined a group of regulatory
T cells (Tregs) that are critical for both central and peripheral
tolerance. Loss-of-function mutations in the transcription fac-
tor forkhead box P3 (FOXP3) cause a fatal autoimmune disor-
der in humans known as immunodysregulation polyendocrin-
opathy enteropathy X-linked (IPEX) syndrome. Similarly,
Foxp3/ mice exhibit multi-organ autoinflammatory disease
and early mortality (Bennett et al., 2001). In addition, the ability
to generate or ‘‘induce’’ Tregs from the pool of helper T cells in
the periphery in order to become tolerant to innocuous foreign
antigens such as food and commensal microbes at mucosal
surfaces is equally important for mucosal immune homeostasis
(Atarashi et al., 2013; Hauet-Broere et al., 2003). The mecha-
nisms by which Tregs exert their immunoregulatory function
in the intestine are thought to occur via production of soluble
mediators and/or direct interactions with other immune cells
(Mayne and Williams, 2013). In recent years, a subpopulation
of FOXP3 interleukin (IL)10-secreting iTregs (termed Tr1 cells)
has been implicated in the regulation of intestinal inflammation
(Groux et al., 1997). This critical role for IL10 signaling in main-
taining intestinal immune homeostasis is best exemplified by
the observation that loss-of-function mutations in IL10 or the
IL10 receptor cause IBD in both mice and humans (Glocker
et al., 2009; K€uhn et al., 1993). Because Tregs are thought to
play a central role in preventing IBD (Josefowicz et al., 2012;
Mayne and Williams, 2013; Sakaguchi et al., 2010), generationors.
creativecommons.org/licenses/by-nc-nd/4.0/).
or expansion of functional Tregs constitutes an attractive ther-
apeutic approach to treat IBD (Canavan et al., 2016), and ther-
apeutic strategies aimed at expanding Tregs in vivo have
proved effective in controlling other immune-mediated disor-
ders (Koreth et al., 2011; Saadoun et al., 2011; Desreumaux
et al., 2012).
Though several polymorphisms have been associated with
altered risk for IBD, surprisingly, only one-third of the disease
is explained by genetics, suggesting that environmental trig-
gers play an important role. The aryl hydrocarbon receptor
(AHR) is a ligand-activated transcription factor that senses
certain environmental chemicals and has been shown to exert
significant effects on the immune response. Previous work
from our group and others demonstrates a role for AHR in
the differentiation and function of Tregs and effector T cells
by controlling the production of IL10 and IL22 (Apetoh et al.,
2010; Gandhi et al., 2010; Quintana et al., 2008; Yeste et al.,
2014; Mascanfroni et al., 2015). In mice, activation of AHR sup-
presses experimental colitis, and although no current therapies
target AHR in humans, the expression of AHR is increased in
IBD lesions (Arsenescu et al., 2011; Benson and Shepherd,
2011; Chinen et al., 2015; Fukumoto et al., 2014; Furumatsu
et al., 2011; Monteleone et al., 2011). Given the importance
of Tregs in intestinal homeostasis, coupled with the immuno-
modulatory effects of IL10 and IL22 downstream of AHR
activation (Mayne and Williams, 2013; Sonnenberg et al.,
2011), AHR is an attractive therapeutic target. The exogenous
small molecule 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD)
has been shown to activate AHR; however, toxicity prevents
the use of TCDD for therapeutic intervention in patients.
Thus, there is a need not only for non-toxic AHR agonists but
also for the establishment of new experimental systems to eval-
uate the effects of AHR activation on human cells in the context
of intestinal inflammation in vivo. In this report, we investigated
the effects of the mucosal non-toxic AHR agonist 2-(10H-indole-
30-carbonyl)-thiazole-4-carboxylic acid methyl ester (ITE) (Song
et al., 2002) on human T cells in vitro and developed a new
experimental model of IBD driven by human CD4+ T cells in hu-
manized mice to assess the efficacy of AHR activation by ITE
in vivo. We found that AHR activation by ITE induces suppres-
sive human Tregs expressing Granzyme B (GZMB), CD39, IL10,
and FOXP3 and prevents T-cell-driven colitis in humanized
mice. Future studies will address whether ITE is effective in
treating established disease, which will be an important step
to determine whether ITE would be an attractive candidate
for the therapeutic induction of Tregs to treat patients with
established IBD.
RESULTS
ITE Induces Tregs through a Mechanism Mediated
by AHR
The induction of Tregs and the re-establishment of immune
tolerance is a potential approach for the long-term treatment
of IBD and other inflammatory diseases and may minimize
the deleterious side effects associated with immunosuppres-
sive approaches now in use (Chatenoud, 2015). We and
others have shown that AHR activation induces Tregs thatsuppress the development of experimental autoimmunity
and inflammation (Apetoh et al., 2010; Kerkvliet et al., 2009;
Quintana et al., 2008). Although AHR activation with TCDD in-
duces functional human Tregs, toxicity concerns exclude its
use as therapeutic agent (Gandhi et al., 2010). We therefore
investigated the effects of the non-toxic AHR agonist ITE iso-
lated from mucosal tissue (Song et al., 2002). Naive CD4+
T cells from peripheral blood mononuclear cells (PBMCs) of
healthy donors were sorted based on CD4+CD62L+CD45RO
(Figure S1) and co-cultured with autologous unfractionated
CD4+ T cells, previously treated with ITE, TCDD, or vehicle
control, in the presence of anti-CD3/anti-CD28 antibodies
with IL2. ITE treatment induced suppressive activity in human
T cells in vitro that was comparable to the suppressive activity
observed using TCDD as a positive control (Figure 1A). We
confirmed the activation of AHR by ITE using quantitative
real-time PCR (qPCR) to detect an increase in the expression
of the AHR transcriptional target CYP1A1 (Figure 1B). To test
whether the induction of suppressive T cells by ITE was
mediated by AHR, we targeted AHR using small interfering
RNA (siRNA) that abrogated the suppressive effect of ITE
and then corroborated these findings using a selective AHR
antagonist CH223191 that also blocked ITE-mediated sup-
pression in vitro (Figure 1C).
To further investigate activation of AHR by ITE in human
T cells, we analyzed the expression of cytokines and line-
age-specific molecules and transcription factors associated
with different CD4+ T cell subpopulations by qPCR. ITE treat-
ment decreased expression of TBX21, RORC, and IL23R
but not GATA3 (Figures 1D and S2), which correlates with
reduced effector T cell subsets. In contrast, T cell activation
in the presence of ITE led to significant upregulation of
Treg-associated gene transcripts, including FOXP3, IL10,
GZMB, ENTPD1, and IKZF3 (Figures 1E and S2) (Groux
et al., 1997; Quintana et al., 2012; Sakaguchi et al., 2010).
ITE treatment had a modest or no effect on the expression
of MAF, BCL6, BLIMP, IL12RB1, or IL12RB2 (Figure S2).
Based on the transcriptional analysis, we then profiled
ITE-treated CD4+ T cells to assess protein expression for
TBX21, RORC, GATA3, FOXP3, IL10, GZMB, and CD39
(encoded by ENTPD1) by flow cytometry and found it to be
consistent with the transcriptional analysis (Figures 1F and
1G). Although many of these markers are consistent with
traditional Foxp3 IL10+ Tr1 regulatory cells, a large percent-
age of ITE-treated T cells expressing CD39 were also positive
for FOXP3+, suggesting that ITE induces a mixed population
of regulatory cells, with only some possessing a conventional
Tr1 phenotype (Figure S3).
The ability of Tregs to control the activity of effector T cells can
occur via several mechanisms (Josefowicz et al., 2012; Sakagu-
chi et al., 2010). Specifically, GZMB, CD39, and IL10 are known
to contribute to the suppressive activity of Tr1 cells (Gandhi
et al., 2010; Grossman et al., 2004; Mascanfroni et al., 2015).
To determine whether the suppressive effect of ITE was medi-
ated by GZMB, we first performed suppression assays in
the presence of the GZMB inhibitor benzyloxycarbonyl-Ala-
Ala-Asp-chloromethylketone (AAD-CMK) and found that ITE-
and TCDD-mediated suppression was abrogated (Figure 1H).Cell Reports 17, 1318–1329, October 25, 2016 1319
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Figure 1. ITE Induces Suppressive Human Tregs through a Mechanism Mediated by AHR
(A) Suppressive activity of human naive CD4+ T cells activated with plate-bound aCD3/aCD28 and IL-2 in the presence of vehicle (CTL), ITE, or TCDD. Percent
suppression is depicted as the mean ± SEM pooled from at least three independent experiments (n = 21).
(B) Relative expression of the AHR target CYP1A1 following stimulation with aCD3/aCD28 and IL-2 in the presence of ITE or TCDD and compared to PBS vehicle
control. Data are depicted as the mean ± SEM (n = 16).
(C) Requirement for AHR for the suppressive effect of ITE. Relative suppression following siRNA-mediated knockdown of AHR compared to scrambled siRNA as
control (left). Percent T cell suppression by ITE in the presence of 10 mMCH223191, a selective antagonist of AHR, compared to DMSO as vehicle control. Results
are depicted as the mean ± SEM pooled from two independent experiments.
(D and E) qPCR analysis of RNA isolated from T cells stimulated with aCD3/aCD28 and IL-2 in the presence of vehicle, ITE, or TCDD. Target fold change was
calculated using vehicle control, with the dashed line representing the normalized control value of 1 and the mean depicted as ±SEM pooled from three inde-
pendent experiments (nR 7).
(F and G) Representative flow cytometric analysis of TBX21, GATA3, RORC, FOXP3, IL10, GZMB, and CD39 protein expression following T cell activation using
aCD3/aCD28 and IL-2 in the presence or absence of ITE for 6 days. Each flow panel is representative of at least two independent experiments.
(H) Requirement for GZMB and CD39 for the suppressive activity of ITE using a blocking antibody against CD39 or the GZMB inhibitor AAD-CMK (left) and
showing the requirement for GZMB and CD39 for TCDD-mediated suppression as a positive control (right). n = 21.
(I) Role of IL10 in ITE-mediated T cell suppression using 2.5 mg mL1 of aIL10 blocking antibody shown as percent suppression (left) and the ability of aIL10
antibody to inhibit STAT3 phosphorylation in human T cells following a 20 min stimulation with 20 ng mL1 of IL10 (right).
*p < 0.05, **p < 0.01, ***p < 0.001; NS, not significant.Because CD39 can also participate in the suppression of
effector T cell responses, we inhibited CD39 using neutralizing
antibodies in ITE-treated T cells. Similar to AAD-CMK, treatment
with anti-CD39 blocked ITE- and TCDD-mediated suppressive
activity in vitro (Figure 1H). Although IL10 was upregulated by
ITE by qPCR, we tested whether antibody-mediated blockade
of IL10 would inhibit suppression. While the anti-IL10 antibody1320 Cell Reports 17, 1318–1329, October 25, 2016effectively blocked the phosphorylation of STAT3 in response
to IL10 (confirming a block in IL10R [interleukin-10 receptor]
signaling), this had no impact on the suppressive effect of ITE
(Figure 1I). Collectively, these results demonstrate that AHR acti-
vation by ITE induces functional human Tregs that suppress
effector T cell proliferation in a GZMB- and CD39-dependent
manner.
ITE Induces Functional Human FOXP3+ Tregs in the
Presence of TGF-b1
Transforming growth factor b1 (TGF-b1) is expressed by both
immune and non-immune cells in the intestinal lamina propria
and regulates the immune response through several mecha-
nisms, one of which consists of the differentiation, mainte-
nance, and function of FOXP3+ Tregs (Rubtsov and Rudensky,
2007). Although TGF-b1 promotes the differentiation of func-
tional FOXP3+ Tregs in mice (Chen et al., 2003), TGF-b1-
induced FOXP3+ human T cells do not exhibit suppressive
activity (Tran et al., 2007). To mimic the TGF-b1-enriched
microenvironment of the intestine, we previously showed that
AHR activation by TCDD could cooperate with TGF-b1-induced
signaling to induce suppressive FOXP3+ human Tregs in vitro
(Gandhi et al., 2010). Therefore, we investigated whether hu-
man Tregs induced using TGF-b1 in the presence of ITE would
mimic the suppressive effects of TCDD. Similar to our findings
with TCDD, human naive CD4+ T cells activated in the presence
of TGF-b1 and ITE were suppressive in vitro (Figure 2A).
Because we previously observed decreased expression of
CD4+ T cell linage-specific transcription factors following ITE
treatment (Figure 1D), we tested whether these molecules
were downregulated under Treg-inducing conditions. CD4+
T cells were treated with vehicle, TGF-b1, or TGF-b1 in the
presence of ITE or TCDD. Although TGF-b1 significantly
reduced expression of TBX21 and GATA3, no further decrease
was observed if ITE or TCDD was present (Figure 2B). TGF-b1
treatment increased RORC expression that was not further
enhanced in the presence of ITE and TCDD; however, these
data did not achieve statistical significance (Figure 2B). The
expression of IL23R was elevated over control when stimulated
with TGF-b1 and ITE, which was not observed in T cells treated
with TGF-b1 alone or in combination with TCDD (Figure 2B). We
then evaluated protein expression of these qPCR targets by
flow cytometry in T cells activated in the presence of vehicle
control, TGF-b1, or TGF-b1 and ITE and observed a reduction
in GATA3, increased expression of RORC, and a slight increase
in TBX21 over control only in the TGF-b1- and ITE-treated cells
(Figure 2C).
Activation of AHR also upregulates the expression of the
Ikaros family transcription factor AIOLOS (encoded by IKZF3)
that silences the IL2 promoter and, along with IL10 and
FOXP3, is associated with suppressive human Tregs (Gandhi
et al., 2010; Quintana et al., 2012; Sakaguchi et al., 2010). We
analyzed Tregs induced with TGF-b1 alone or in the presence
of ITE or TCDD and quantified the expression of IKZF3, IL10,
and FOXP3. Although FOXP3 was elevated in all treatment
conditions compared to control, IL10 and IKZF3 were upregu-
lated by TGF-b1 and ITE (Figures 2D and S4). Flow cytometric
analysis largely supported the transcriptional analysis, whereby
increases in FOXP3, IL10, and CD39 were also observed
(Figure 2E).
Because CD39 and GZMB were required for ITE-induced
AHR-dependent T cell suppression in vitro in the absence of
TGF-b1 (Figure 1H), we determined whetherGZMB and ENTPD1
were also upregulated following AHR activation with ITE or
TCDD under Treg-inducing conditions with TGF-b1. While there
was no increase inGZMB transcript or protein in vitro (Figures 2Dand 2E), ENTPD1 transcript levels trended higher (Figure 2D),
although cell surface expression of CD39 was increased (Fig-
ure 2E). We then tested whether CD39 was required for the sup-
pressive effect of ITE in the presence of TGF-b1. Neutralizing
CD39 abrogated the suppressive activity of T cells treated with
TGF-b1 and ITE, similar to that observed for TGF-b1 and
TCDD and consistent with a role for CD39 in this suppressive
function (Figure 2F). Altogether, these data demonstrate that
AHR activation with ITE in the presence of TGF-b1 induces
functional human Tregs that suppress effector T cells in a
CD39-dependent manner in vitro.
T-Cell-Dependent Colitis Model in Humanized Mice
Most experimental immunotherapies successful in treating
experimental autoimmunity in animal models show limited suc-
cess in human clinical trials (Hay et al., 2014; Persidis, 1999).
One important contributor to the limited translational applica-
tion of experimental findings in mice into successful therapies
for human autoimmunity is the lack of models to study the hu-
man immune system in vivo. Over the past decade, immunode-
ficient mice have been developed that are capable of engrafting
human immune cells (Rongvaux et al., 2014; Shultz et al., 2005;
Traggiai et al., 2004). Although sub-optimal adaptive immune
responses are often observed in many humanized murine
systems, we described non-obese diabetic (NOD).Prkdcscid.
Il2rg/ (NSG) mice that lack murine major histocompatibility
complex (MHC) class II and instead express human leukocyte
antigen (HLA) DR1 under the control of the murine MHC
class II promoter (NSGAbDR1 mice) (Goettel et al., 2015).
These mice intrinsically lack murine lymphocytes, as well as
natural killer (NK) cells, and when made immune replete using
human CD34+ hematopoietic stem cells (HSCs), the mice
displayed improved human CD4+ T cell responses (Goettel
et al., 2015). To specifically evaluate CD4+ T cell responses,
we used a reductionist approach by reconstituting NSGAbDR1
mice with human CD4+ T cells isolated from allelically matched
HLA-DR1+ donors. To evaluate the effects of candidate drugs
on human CD4+ T cells in vivo, we adapted an established
experimental model of intestinal inflammation using the
hapten 2,4,6-trinitrobenzenesulfonic acid (TNBS) that is largely
mediated by T cells (Neurath et al., 1995). Reconstituted
NSGAbDR1 mice were sensitized with TNBS to prime anti-
gen-specific T cells, and 1 week post-sensitization mice were
administered a single rectal enema containing 0.25 mg of
TNBS in 50% ethanol (EtOH) or 50% EtOH as a vehicle control
(Figure 3A). Although reconstituted NSGAbDR1 mice chal-
lenged with TNBS exhibited significant weight loss 3 days
post-challenge, weight loss was not readily observed in recon-
stituted mice challenged with EtOH or in non-reconstituted
mice challenged with TNBS (Figure 3B). Consistent with these
observations, blinded histological evaluation of colonic sec-
tions stained with H&E revealed extensive crypt and goblet
cell loss with edema, fibrosis, and transmural inflammation
in TNBS-treated NSGAbDR1 mice reconstituted with human
CD4+ T but not in control mice (Figure 3C), with a histological
colitis score that was significantly higher in TNBS-treated
reconstituted NSGAbDR1 mice compared to controls (Fig-
ure 3D). This correlated with an increase in CD4+ T cellsCell Reports 17, 1318–1329, October 25, 2016 1321
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Figure 2. ITE Induces Functional Human FOXP3+ Tregs in the Presence of TGF-b1
(A) Suppressive activity of human naive CD4+ T cells activated with aCD3/aCD28 and TGF-b1 in the presence of CTL, ITE, or TCDD. Percent suppression is
depicted as the mean ± SEM pooled from at least two independent experiments with ten unique donors.
(B) qPCR analysis on RNA isolated from T cells stimulated with aCD3/aCD28 and IL-2 in the presence of CTL, TGF-b1, TGF-b1 + ITE, or TGF-b1 + TCDD. Target
fold change was calculated using vehicle control, with the dashed line representing the normalized control value of 1 and relative expression shown as the pooled
mean ± SEM (nR 10).
(C) Representative flow cytometric analysis of TBX21, GATA3, and RORC protein expression in T cells following activation using aCD3/aCD28 and IL-2 in the
presence of CTL, TGF-b1, or TGF-b1 + ITE from three independent experiments.
(D) qPCR analysis on RNA isolated from T cells stimulated with aCD3/aCD28 in the presence of CTL, TGF-b1, TGF-b1 + ITE, or TGF-b1 + TCDD. Target fold
change was calculated using vehicle control, with the dashed line representing the normalized control value of 1 and relative expression shown as the pooled
mean ± SEM (nR 7). zp < 0.05 compared to control.
(E) Representative flow cytometric analysis of FOXP3, IL10, CD39, and GZMB protein expression in T cells following activation using aCD3/aCD28 and IL-2 in the
presence of CTL, TGF-b1, or TGF-b1 + ITE from two independent experiments.
(F) Effect of CD39 blockade using CD39 blocking antibodies on the suppressive activity of TGF + ITE (left panel) or TGF + TCDD (right panel), with the mean
depicted as ±SEM (nR 12).
*p < 0.05, **p < 0.01, ***p < 0.001.infiltrating in the colonic lamina propria in TNBS-treated, but
not EtOH-treated, mice (Figure 3E).
In the standard model, TNBS-induced colitis leads to the up-
regulation of several pro-inflammatory cytokines including Tnf,
Il2, Il12a, and Ifng (Hollenbach et al., 2005; Neurath et al.,
1997). We analyzed the expression of human cytokines in the co-
lons of TNBS- or EtOH-treated NSGAbDR1 mice by qPCR and
found increased expression of TNF, IFNG, IL2, IL4, and IL17A1322 Cell Reports 17, 1318–1329, October 25, 2016(Figure 3F). Moreover, human T cells recovered from the colonic
lamina propria of TNBS-treated mice showed increased produc-
tion of TNF and interferon g (IFN-g) following ex vivo stimulation
with phorbol 12-myristate 13-acetate (PMA) and ionomycin (Fig-
ure 3G). Collectively, these data show that human CD4+ T cells
mediate disease pathology in TNBS-induced colitis in human-
ized NSGAbDR1 mice. Moreover, these data support the use
of this humanized model to assess the efficacy of therapeutics
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Figure 3. TNBS-Induced Colitis Mediated by Human CD4+ T Cells
(A) Schematic of human CD4+ T cell reconstitution and TNBS experimental colitis in NSGAbDR1 mice.
(B) Change in body weight in NSGAbDR1 mice reconstituted with human CD4+ T cells 3 days following rectal administration of EtOH as a vehicle control (n = 6),
TNBS (n = 9), or NSGAbDR1mice without human T cells administered TNBS (n = 7). Each dot represents an individual animal, with the mean depicted as ±SEM.
Data shown are pooled from three independent experiments and are representative of more than six experiments with similar results.
(C) Endoscopic images of representative mice 3 days following TNBS or EtOH challenge (top), with representative H&E-stained colonic sections (bottom) from
three independent experiments (103 magnification).
(D) Colitis scoring of H&E-stained colon sections 3 days following the TNBS or EtOH rectal challenge. Scores for each mouse are shown, with the mean for each
group depicted as ±SEM.
(E) Representative microscopic images of formalin-fixed, paraffin-embedded colonic sections stained for human CD3 from NSGAbDR1 mice previously re-
constituted with human CD4+ T cells treated with EtOH or TNBS (n = 4) (left) and quantified (right) with bars representing the mean ± SEM (203 magnification).
(F) qPCR analysis on RNA isolated from colonic tissue of reconstituted NSGAbDR1 mice treated with TNBS or EtOH (n = 6). Human cytokines were normalized
to hypoxanthine phosphoribosyltransferase (HPRT), and the fold change was compared to a pooled human RNA control sample using the formula
2(Ct(target)Ct(HPRT)). Bars represent the mean ± SEM.
(G) Representative flow cytometric analysis of human CD4+ T cells isolated from the colonic lamina propria of NSGAbDR1 mice stimulated with PMA and
ionomycin for 4 hr in the presence of GolgiStop and then stained for intracellular TNF and IFN-g (top) and quantified (bottom) from three independent experiments
(nR 5).
Scale bars, 200 mm. *p < 0.05, **p < 0.01, ***p < 0.001.that target human CD4+ T cells in promoting intestinal immune
homeostasis. Consistent with our results, recent studies have
showed that the homology of MAdCAM-1 between mice and
humans permits binding of human a4b7 integrin to murine
MAdCAM-1 and that human CD4+ T cells injected into DSS-
treated NSG mice migrate to the colon (Fischer et al., 2016).
ITE Prevents T-Cell-Driven Experimental Colitis in
Humanized Mice
To investigate the effects of ITE on human T cells in vivo, we used
the humanized mouse model described earlier, and 1 week
following engraftment of human CD4+ T cells, mice were admin-
istered daily injections of ITE or PBS as a vehicle control for
5 days. The day following the last ITE or PBS injection, mice
were sensitized to TNBS and 1 week later administered a single
TNBS rectal challenge (Figure 4A). The administration of ITE to
humanized mice followed by the TNBS challenge resulted in atrend in protection against weight loss compared to control (Fig-
ure 4B). Histological evaluation of H&E-stained colonic sections
showed a significant reduction in the severity of inflammation in
mice receiving ITE that corresponded to a reduction in colitis
score (Figures 4C). This reduction in colitis by ITE correlated
with an increase in the frequency of regulatory human T cells in
the colon based on increased expression of GZMB, CD39,
IL10, and FOXP3 by flow cytometry (Figures 4D). These data
are highly similar to the effects of ITE on human CD4+ T cells
observed in vitro (Figure 1). We further investigated the conse-
quences of ITE treatment on human T cells in vivo by analyzing
the transcriptional profile of CD4+ T cells isolated from the
spleens of ITE- or PBS-treated mice using Nanostring nCounter
arrays. ITE treatment upregulated the expression of several tran-
scription factors andmolecules linked to anti-inflammatory path-
ways in human T cells, including IL10, IL21, IL22, IL32, GZMB,
IKZF2, and IKZF3 (Figure S4A) (Evans et al., 2014; GandhiCell Reports 17, 1318–1329, October 25, 2016 1323
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Figure 4. ITE Prevents T-Cell-Driven Experimental Colitis in Humanized Mice
(A) Schematic of ITE administration in TNBS experimental colitis in NSGAbDR1 mice reconstituted with human CD4+ T cells.
(B) Body weight change 3 days following TNBS rectal challenge in NSGAbDR1mice reconstituted with HLA-DR1-matched human CD4+ T cells treated with PBS
(n = 8) or ITE (n = 13). Each dot represents an individual mouse, with the mean depicted as ±SEM pooled from three independent experiments using two unique
HLA-DR1-matched healthy donor sources.
(C) Representative H&E-stained colonic sections 3 days post-TNBS challenge of reconstituted NSGAbDR1mice treated with PBS (n = 8) or ITE (n = 13) (left), and
colitis score quantified with the mean for each group depicted as ±SEM pooled from three independent experiments with two unique donor sources (right).
(D) Quantified flow cytometric data of human CD4+ T cells isolated from the spleen and colonic lamina propria of PBS- or ITE-treated NSGAbDR1 mice stained
for humanCD45 (hCD45), GZMB, CD39, and FOXP3 (top), with representative dot plots shown below. Intracellular IL10 staining was performed on T cells isolated
from spleen and colonic lamina propria and stimulated ex vivo with PMA and ionomycin for 4 hr in the presence of GolgiStop. Bars represent the mean ± SEM
pooled from two independent experiments using two unique HLA-DR1-matched healthy donors.
(E) Schematic depicting injection of in vitro-generated autologous ITE-induced suppressive T cells before rectal challenge with TNBS in NSGAbDR1 mice
previously reconstituted with matched donor CD4+ T cells.
(F) Flow cytometry dot plot showing the recovery of in vitro-generated autologous Tregs (labeled with CellTrace violet before intraperitoneal injection of 23 106
labeled cells) from spleens of humanized mice.
(G) Body weight change 3 days following TNBS rectal challenge in NSGAbDR1mice reconstitutedwith HLA-DR1-matched humanCD4+ T cells and injectedwith
PBS (n = 9) or autologous in vitro ITE-generated suppressive cells (n = 7) 1 day before TNBS rectal challenge. Each dot represents an individual mouse, with the
mean depicted as ±SEM pooled from two independent experiments using two unique HLA-DR1-matched healthy donor sources.
(H) Representative H&E-stained colonic sections 3 days post-TNBS challenge of reconstituted NSGAbDR1 mice injected with PBS (n = 9) or CellTrace violet-
labeled autologous ITE-induced Tregs (n = 7) (left), and colitis score quantified with the mean for each group depicted as ±SEM pooled from two independent
experiments (right).
Images are 203 magnification. Scale bars, 100 mm. *p < 0.05.et al., 2010; Quintana et al., 2012; Sakaguchi et al., 2010).
Although ITE induced cytokine transcripts known to be both
pro- and anti-inflammatory, pathway analysis and functional
gene clustering determined that the most affected gene
sets were linked to several pathways relevant for IBD pathogen-1324 Cell Reports 17, 1318–1329, October 25, 2016esis with significant downregulation in TNFR1, death receptor
signaling, and nuclear factor kB (NF-kB) signaling (Figure S4B).
Conversely, ITE treatment led to an upregulation of IL22 (Fig-
ure S4B), a known target of AHR linked to the protection of the
intestinal epithelium (Sonnenberg et al., 2011; Yeste et al., 2014).
Expression of AHR is not restricted to immune cells, and
although our data suggest that the suppressive effects of ITE
in vivo were likely mediated by the effects on human CD4+
T cells, we cannot exclude the possibility that the therapeutic
benefit of ITE in TNBS-induced colitis is mediated by the
activation of AHR in murine cells. To directly test whether
AHR activation by ITE in human T cells was sufficient to atten-
uate TNBS colitis in humanized mice, we first reconstituted
NSGAbDR1 mice with HLA-matched donor CD4+ T cells. We
then initiated in vitro cultures of autologous human CD4+
T cells as before to induce suppressive T cells. After 6 days of
culture, we labeled the autologous ITE-treated T cells with
CellTrace violet and injected 23 106 cells per mouse.We admin-
istered the rectal TNBS challenge the next day (Figure 4E). We
euthanized themice 3 days post-TNBS challenge and confirmed
the presence of the in vitro-cultured Tregs based on CellTrace vi-
olet staining (Figure 4F). Humanized mice receiving ITE-treated
cells more readily recovered to their initial body weight with
less colonic inflammation and a significantly improved colitis
score (Figures 4G and 4H). Thus, autologous Tregs generated
in vitro were sufficient to protect against TNBS-mediated colitis
in humanized mice.
DISCUSSION
Current strategies for the long-term treatment of IBD and other
inflammatory diseases often depend on broad immunosuppres-
sion that can cause deleterious side effects. Unfortunately, most
experimental immunotherapies developed using rodent models
have had limited success in human clinical trials (Hay et al.,
2014; Persidis, 1999). This is likely due, at least in part, to
inherent physiological differences in immune cells between
mice and humans. We previously described improved human
T cell responses in NSGAbDR1 mice that express human, but
not murine, MHC class II. Moreover, when these mice were re-
constituted using HSCs isolated from an IPEX patient lacking
functional FOXP3 and Tregs (Goettel et al., 2015), the mice
developed amulti-organ inflammatory syndrome, with the devel-
opment of autoantibodies analogous to patients. We expanded
upon this model and demonstrated that in the presence of
normal human T cells, TNBS administration to NSGAbDR1
mice resulted in severe intestinal inflammation. Because the
re-establishment of immune tolerance in immune-mediated
diseases has shown early promise in the clinical setting through
the induction or expansion of autologous Tregs (Desreumaux
et al., 2012; Koreth et al., 2011), we investigated whether an
endogenous ligand to AHR could induce human Tregs and
have a therapeutic effect in a humanized mouse model of intes-
tinal inflammation. We and others have previously shown that
AHR activation induces Tregs that suppress the development
of inflammation and experimental autoimmunity in mice (Apetoh
et al., 2010; Kerkvliet et al., 2009; Mascanfroni et al., 2015; Quin-
tana et al., 2008, 2010; Vogel et al., 2008; Wu et al., 2011; Yeste
et al., 2012, 2014; Zhang et al., 2009). Although AHR activation
with TCDD induces functional human Tregs in vitro, toxicity
prevents the use of TCDD as a therapeutic in humans (Gandhi
et al., 2010). Here we demonstrate that the non-toxic AHR
agonist ITE induces functional human Tregs that suppresseffector T cell proliferation in a CD39- and GZMB-dependent
manner in vitro. Furthermore, we employed the TNBS human
CD4+ T cell mouse model of colitis described earlier and demon-
strated that ITE promoted mucosal immune homeostasis and
was protective against colitis development.
For many inflammatory diseases, the effector cytokine profile
of CD4+ T cells can be informative and, in some cases, indicative
of the T cell subset or subsets involved in disease pathogenesis.
The polarization of CD4+ T cells into these specific subsets is
highly regulated by transcription factors that drive Th1, Th2,
and Th17 differentiation, namely, TBX21, GATA3, and RORC,
respectively. We found that ITE, like the toxic AHR ligand
TCDD (Gandhi et al., 2010), downregulated Th1 and Th17 tran-
scription factors TBX21 and RORC, although the expressions
of molecules associated with Treg suppressive function,
including IL10, FOXP3, GZMB, and ENTPD1, were increased.
This suggests that the suppression of effector T cells by ITE likely
occurs by restricting differentiation of Th1 and Th17 effector sub-
sets, in addition to inducing immunoregulatory molecules asso-
ciated with Tregs. Because IL10, GZMB, and CD39 are known to
participate in T cell suppression by Tregs, we tested whether the
suppressive effects of ITE were mediated by any of these three
molecules. ITE-mediated suppression in the absence of TGF-
b1 was dependent on GZMB and CD39 as pharmacological or
antibody-mediated inhibition blocked suppression. Under
Treg-inducing conditions with TGFb, ITE did not alter the expres-
sion of GZMB or ENTPD1, whereas protein levels of CD39 were
increased at the cell surface. This suggests that AHR activation
by ITE may mobilize intracellular pools of CD39 to the plasma
membrane. Although CD39 is an important molecule in Tr1 cell
differentiation and function (Mascanfroni et al., 2015) and was
involved in the suppressive effect of ITE in vitro, it appears that
the suppressive cells induced by ITE may be a mixed population
of FOXP3 Tr1 cells expressing traditional markers CD39,
GZMB, and IL10, as well as FOXP3+ Tregs. We also observed
a population of CD39+ cells that were positive for FOXP3 and
may constitute a Tr1-like cell population previously described
to possess a regulatory phenotype (Borsellino et al., 2007; Dea-
glio et al., 2007; Moncrieffe et al., 2010).
Although IBD is a complex disorder triggered by genetic, envi-
ronmental, and microbial factors, genome-wide association
studies have identified more than 160 polymorphisms associ-
ated with altered risk for IBD (Jostins et al., 2012). Many of these
mutations are known to regulate immune responses, with
several being enriched in immune cells, in particular CD4+
T cells and dendritic cells (Jostins et al., 2012). Although poly-
morphisms in AHR have not yet been associated with IBD,
AHR is known to play a central role in the regulation of intestinal
inflammation and is upregulated in the inflamed gut (Arsenescu
et al., 2011; Benson andShepherd, 2011; Chinen et al., 2015; Fu-
kumoto et al., 2014; Furumatsu et al., 2011; Huang et al., 2013; Ji
et al., 2015; Mascanfroni et al., 2015; Monteleone et al., 2011;
Qiu et al., 2013; Quintana et al., 2012; Singh et al., 2011; Taka-
mura et al., 2010, 2011; Yeste et al., 2014). We and others previ-
ously showed that in T cells, AHR controls the production of IL10
(Apetoh et al., 2010; Gandhi et al., 2010;Mascanfroni et al., 2015;
Wu et al., 2011) and IL-22 (Quintana et al., 2008; Veldhoen et al.,
2008, 2009; Yeste et al., 2014) to modulate and promoteCell Reports 17, 1318–1329, October 25, 2016 1325
immunological tolerance in the intestine. Consistent with these
previous findings, our present data demonstrate that AHR acti-
vation by ITE induces a transcriptional program in human CD4+
T cells that promotes IL22 and IL10 expression in vivo.Moreover,
ITE treatment led to an increase in GZMB, CD39, IL10, and
FOXP3, particularly in the colon of humanized mice, and attenu-
ated intestinal inflammation induced by TNBS. Although our
in vivo data are consistent with in vitro findings for ITE inducing
suppressive CD4+ T cells, we cannot exclude the possibility
that some of the protective effects of ITE in vivo could also be
mediated by other cells types that express AHR, including intes-
tinal epithelial cells and murine innate immune cells (Esser and
Rannug, 2015). Nevertheless, we showed that in vitro-generated
autologous ITE-treated T cells could be administered just before
the TNBS challenge and protect against TNBS-induced colitis in
humanized mice. Further investigations on ITE using human
CD4+ T cell reconstituted NSGAbDR1 mice with established
TNBS-induced colitis are warranted prior to clinical application
aimed at treating IBD.
In conclusion, we have demonstrated that AHR activation with
the non-toxic agonist ITE induces, in the presence or absence of
TGF-b1, human Tregs in vitro that can suppress effector T cell
proliferation in a CD39- and GZMB-dependent manner. Given
the inability to readily assess therapeutics in patients, we devel-
oped a humanized murine system to directly assess the ability of
ITE, as well as other agents, to modulate human CD4+ T cell
responses in vivo. We showed that TNBS-induced colitis in
humanizedmice requires human CD4+ T cells and that ITE atten-
uated colitis development, promoting immunological tolerance.
This model has the advantage that it does not require full human
immune reconstitution using HSCs and can be established using
T cells from healthy controls, as well as patient cells. The use of
this model will facilitate evaluation of potential treatments for IBD
and, more importantly, investigations into the inflammatory
response of human CD4+ T cells from patients with mutations
in loci associated with altered risk for IBD, including IL10R or
IL23R (Duerr et al., 2006; Glocker et al., 2009; Sarin et al.,
2011). This may enable clinicians to stratify patients and distin-
guish responders versus non-responders, leading to tailored
therapeutics.
EXPERIMENTAL PROCEDURES
Antibodies and Reagents
The following flow cytometry antibodies were obtained through BioLegend:
FOXP3, clone 259D; CD39, clone A1; CD45, clone HI30; CD4, clone OKT4;
GZMB, clone GB11; TNF, clone MAb11; and IFNG, clone 4S.B3. The following
flow cytometry antibodies were obtained through eBioscience: GATA3, clone
TWAJ; TBX21, clone eBio4B10; and RORC, clone AFKJS-9. IL10, clone JES3-
19F1, was obtained through BD Biosciences. Anti-CD3, clone OKT3, and anti-
CD28, clone CD28.6, were used for in vitro stimulation and purchased through
eBioscience. TGF-b1 was obtained from R&D Systems. Human recombinant
IL-2 was obtained from the AIDS Research and Reference Reagent Program,
National Institute of Allergy and Infectious Diseases (NIAID). Annexin V-PE/
FITC and 7-AAD were obtained from BD Biosciences.
Isolation of Naive T Cells
Blood samples were collected from healthy controls upon informed consent.
The institutional review board at Brigham and Women’s Hospital approved
all procedures described in this work. PBMCs were obtained by Ficoll density1326 Cell Reports 17, 1318–1329, October 25, 2016gradient. Total CD4+ T cells were purified using Miltenyi Biotec AutoMACS,
and CD62Lhigh and CD45RO T cells were purified by fluorescence-activated
cell sorting (FACS) using FACSAria (BD Biosciences) to typically obtain 96%–
98% purity in post-sort analysis.
T Cell Differentiation
After FACS, naive T cells were activated with plate-bound antibodies to
CD3 (1 mg mL1), soluble CD28 (1 mg mL1), and human recombinant IL-2
(50 U/mL) with or without TGF-b1 (1 ng mL1), in the presence or absence of
100 nM ITE. After 6 days of differentiation, the cells were resorted to exclude
dead cells and were used for suppression assays or analyzed by FACS or
qPCR.
Suppression Assays
Responder T cells (CD4+ T cells) were activated with beads coated with anti-
bodies to CD3 and CD28 (1 mg/107) for 5 days in the presence of Tregs at a 2:1
(responder to regulatory) ratio. Cells were pulsedwith 3H-thymidine (1 mCi/well)
for 16–24 hr at the end of the incubation period. Anti-IL10 (clone 25209) was
purchased from R&D Systems and used at 2.5 mg mL1. CH223191 was
purchased from Tocris and was used at 10 mM.
Quantitative Real-Time PCR
RNA was extracted with QIAGEN RNAeasy columns; cDNA was prepared
following the manufacturer’s instructions (Applied Biosystems) and used as
a template for real-time PCR. All primers and probes in this workwere provided
by Applied Biosystems and were used on the GeneAmp 7500 Sequence
Detection System (Applied Biosystems). Expression was normalized to the
expression of GAPDH. All murine qPCR primers and reagents were obtained
from Applied Biosystems.
For humanizedmouse studies, qPCRwas performedwith SYBRGreen (Bio-
Rad) using a CFX96 real-time PCR (Bio-Rad) machine on cDNA generated with
the iScript cDNA kit (Bio-Rad) on 1 mg of total RNA isolated from whole tissue
homogenized in TRIzol (Life Technologies). Then, 2 mM of each human target
primer was used in the reaction and quantified by normalizing the cycle
threshold (Ct) of the target gene to the Ct value of HPRT, and the fold change
was compared to a pooled human RNA control sample using the formula
2(Ct(target)Ct(HPRT)).
Sequences for human targets are as follows:
IFNG: forward, 50-TCGGTAACTGACTTGAATGTCCA-30; reverse, 50-TCG
CTTCCCTGTTTTAGCTGC-30
TNF: forward, 50-GAGGCCAAGCCCTGGTATG-30; reverse, 50-CGGG
CCGATTGATCTCAGC-30
IL10: forward, 50-GACTTTAAGGGTTACCTGGGTTG-30; reverse, 50-TCA
CATGCGCCTTGATGTCTG-30
IL17A: forward, 50-TCCCACGAAATCCAGGATGC-30; reverse, 50-GGAT
GTTCAGGTTGACCATCAC-30
IL4: forward, 50-CGGCAACTTTGTCCACGGA-30; reverse, 50-TCTGTT
ACGGTCAACTCGGTG-30
IL2: forward, 50-AACTCCTGTCTTGCATTGCAC-30; reverse, 50-GCTCC
AGTTGTAGCTGTGTTT-30
HPRT: forward, 50-CCTGGCGTCGTGATTAGTGAT-30; reverse, 50-AGACG
TTCAGTCCTGTCCATAA-30
TNBS-Induced Colitis and ITE Treatment in Humanized Mice
The generation of NOD.Cg-PrkdcscidIl2rgtm1WjlH2-Ab1tm1D i.Tg(HLA-DRA*0101,
HLA-DRB1*0101) mice (NSGAbDR1) was previously described (Goettel
et al., 2015). Mice were maintained in autoclaved cages with autoclaved food
and water ad libitum in the specific pathogen-free facility at Boston Children’s
Hospital. All animal experiments were approved and conducted according
to the institutional guidelines at Boston Children’s Hospital.
The 6–8 week old NSGAbDR1mice were injected intraperitoneally with 23
106 human CD4+ T cells isolated from a healthy donor that was positive for
the HLA-DRB*0101 allele were purchased from STEMCELL Technologies.
Then, 2–3 weeks later, mice were bled and screened for human T cell recon-
stitution and mice exhibiting greater than 10% human chimerism in peripheral
blood were selected for experimental groups. Mice were first sensitized by
applying 150 mL of a 2.5% TNBS (Sigma-Aldrich) solution in 50% EtOH to a
1 cm2 patch of bare skin at the base of the neck. Seven days later, mice
were anesthetized via a single intraperitoneal injection of saline containing
100 mg kg1 of ketamine and 10 mg kg1 of xylazine. Anesthetized mice
were held inverted by hand, and a sterile lubricated 3.5 F soft silicon catheter
inserted into the colon to a distance of 3–4 cm.Micewere given a single enema
containing 0.25 mg of TNBS in a 50% EtOH, 50% PBS mixture in a volume of
50 mL. Mice were then held inverted for 30 s and returned to their cage. Mice
were weighed daily, and colitis was assessed 3 days after the TNBS rectal
challenge. Histological assessment was performed and scored using a
modified system as previously described (Scheiffele and Fuss, 2002). For
ITE-treated mice, 200 mg of ITE dissolved in PBS was administered intraperi-
toneally starting 1 week after injection of human CD4+ T cells for 5 consecutive
days. Mice were then sensitized and challenged as earlier.
Analysis of Cytokine Production by T Cells in Humanized Mice
Total splenocytes and colonic lamina propria cells were plated at a concentra-
tion of 13 106 cells in RPMI 1640 supplemented with 10% fetal bovine serum
(FBS), 2 mM L-glutamine, 1 mM sodium pyruvate, 100 mM non-essential
amino acids, 10 mM HEPES, 55 mM 2-mercaptoethanol, and 100 U/mL peni-
cillin/streptomycin (Life Technologies) (hereafter referred to as T cell media).
Cells were stimulated with stimulated with 20 ng mL1 PMA and 1 mg mL1
ionomycin (Sigma-Aldrich) for 4 hr at 37C in the presence of 10 mg mL1
GolgiStop (BD Biosciences). Cells were collected and washed 23 with
FACS buffer (PBS supplemented with 2% FBS and 0.1% NaN3). Cell surface
staining for human CD4 was performed for 30 min at room temperature (RT),
washed 23 with FACS buffer, and then fixed using BD Cytofix/Cytoperm
(BD Biosciences) following the manufacturer’s protocol. Cells were then
stained with IFN-g and TNF for 45 min at RT. Cells were washed 23 with
FACS buffer, and intracellular cytokine production was detected using a
three-laser FACSCanto II (BD Biosciences) flow cytometer.
Immunohistochemistry
Histopathology was carried out on formalin-fixed, paraffin-embedded colonic
tissue sections stained with an anti-human CD3 antibody (cat# A0452, Dako).
Images were acquired using an Olympus microscope mounted with an
Olympus DP70 digital camera and DP-Manager software (Olympus) and
were quantified using ImageJ software (NIH).
Statistical Analysis
Statistical analyses were performed using the Prism software (GraphPad), and
t tests were used in Figures 1, 2, 3E–3G, 4B–4D, 4G, 4H, and S2. ANOVA with
multiple comparisons was used in Figures 3B and 3D. p < 0.05 was considered
significant.
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